Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study

• Published in: Nutrients Vol. 16; no. 21; p. 3788
• Main Authors: Lago-Sampedro, Ana, Oualla-Bachiri, Wasima, García-Serrano, Sara, Maldonado-Araque, Cristina, Valdés, Sergio, Doulatram-Gamgaram, Viyey, Olveira, Gabriel, Delgado, Elias, Chaves, Felipe, Castaño, Luis, Calle-Pascual, Alfonso, Franch-Nadal, Josep, Rojo-Martínez, Gemma, García-Escobar, Eva
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04.11.2024; MDPI
• Subjects: Adult; Aged; Blood pressure; Cohort Studies; Cross-sectional studies; Development and progression; Diabetes; Diabetes Mellitus, Type 2 - epidemiology; Diabetes Mellitus, Type 2 - prevention & control; Diet; Diet therapy; Diet, Mediterranean - statistics & numerical data; Disease prevention; Exercise; Fatty liver; Female; Follow-Up Studies; Glucose; Glucose tolerance tests; Humans; Hypertension; Incidence; Insulin resistance; Liver diseases; Male; Metabolic disorders; Middle Aged; Morbidity; Mortality; Non-alcoholic Fatty Liver Disease - epidemiology; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity; Overweight; Patient Compliance - statistics & numerical data; Questionnaires; Risk Factors; Spain - epidemiology; Type 2 diabetes; Variables; Weight control; Weight Gain; Womens health; Spain; MAFLD; Type-2 diabetes incidence; Mediterranean diet; protecting factor
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu16213788

Background/Objectives: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) increases the risk of Type-2 Diabetes (T2DM). The Mediterranean diet (MD) has shown advantages in the management of MAFLD and preventing co-morbidities; however, its relationship with T2DM development in MAFLD has been less investigated. We aimed to evaluate the association of MD adherence with the risk of incident T2DM in the Spanish adult population with MAFLD and according to their weight gain at 7.5 years follow-up. Methods: A cohort of 714 participants (without weight increment: 377; with weight increment: 337) from the Di@bet.es cohort study with MAFLD and without T2DM at baseline were investigated. Anthropometric, sociodemographic, clinical data, and a survey on habits were recorded. OGTT and fasting blood biochemistry determinations were made. Baseline adherence to MD was estimated by the adapted 14-point MEDAS questionnaire and categorized as high and low adherence. Results: In total, 98 people developed T2DM at follow-up. The high adherence to MD was inversely associated with the development of T2DM in both the overall population (0.52 [0.31–0.87]) and subjects without weight gain at follow-up (0.35 [0.16–0.78]). Conclusions: Our results suggest the protective effect of high adherence to MD regarding the risk of T2DM in subjects with MAFLD, with this health benefit being more evident in men with the absence of weight gain. These results support the recommendations for MD use in these patients.